Clinical journal of oncology nursing · 2026
Care of Patients Receiving Abemaciclib: Results From Clinical Trials and a Healthcare Provider Survey.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ginex Pamela K, Thoele Kelli, Ma Qinli, Searles Vitko Alexandra, Gathirua-Mwangi Wambui G, Liepa Astra M, Panjic Elyse H, Chou Engels, Ellis Hilary Jane, de Courcy Joanna, Clewes Charlotte, Taraba Jodi, Rugo Hope S
Аннотация
BACKGROUND: Being familiar with the care of patients with breast cancer who are receiving abemaciclib, including adverse event (AE) management, supports care.
OBJECTIVES: This article describes the care of patients with breast cancer receiving abemaciclib, including AE data from clinical trials and nonpharmacologic interventions in real-world practice through a survey of healthcare providers.
METHODS: Safety data from the monarchE, MONARCH 1, MONARCH 2, and MONARCH 3 trials were reviewed. A quantitative survey of advanced practitioners, oncologists, and pharmacists was also conducted to better understand nonpharmacologic interventions to manage patient-felt AEs and support patients receiving abemaciclib.
FINDINGS: The most common AEs across all MONARCH trials were diarrhea, fatigue, nausea, and neutropenia; most events were grade 1-2. Of 282 survey respondents, more than 90% recommended nonpharmacologic interventions to manage AEs.
OBJECTIVES: This article describes the care of patients with breast cancer receiving abemaciclib, including AE data from clinical trials and nonpharmacologic interventions in real-world practice through a survey of healthcare providers.
METHODS: Safety data from the monarchE, MONARCH 1, MONARCH 2, and MONARCH 3 trials were reviewed. A quantitative survey of advanced practitioners, oncologists, and pharmacists was also conducted to better understand nonpharmacologic interventions to manage patient-felt AEs and support patients receiving abemaciclib.
FINDINGS: The most common AEs across all MONARCH trials were diarrhea, fatigue, nausea, and neutropenia; most events were grade 1-2. Of 282 survey respondents, more than 90% recommended nonpharmacologic interventions to manage AEs.